X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to support the late-stage clinical development of ABP-450, which contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum, being developed for the treatment of episodic migraine.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: AEON Biopharma
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 19, 2024
Details:
DWN12088 (bersiporocin) is a first-in-class prolyl-tRNA synthetase inhibitor, which is being evaluated in phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): DWN12088
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: DWN12088
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Under the terms of the agreement, Zydus will assume full responsibility for the clinical development and commercialization for leuprolide injectable in the US market, and Daewoong will be responsible for the pre-clinical studies, production and supply of the product.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Lupron Depot-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Zydus Lifesciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 12, 2023
Details:
The microneedle patch within the Semaglutide series, a GLP-1 analogue, using its proprietary 'CLOPAM' (Closed-Packed Aeroperssured Microneedle) platform, used for the treatment of Obesity.
Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
HL192 (ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, a master regulator associated with the development and maintenance of dopaminergic neurons, for the potential treatment of Parkinson's Disease.
Lead Product(s): HL192
Therapeutic Area: Neurology Product Name: HL192
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Hanall Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
DWRX2008 is an innovative nanoparticle eyedrop adaptation of Envlo®(enavogliflozin), which tackles the challenge of poor retinal drug absorption from oral use, which is investigated for Diabetic Retinopathy and Macular Edema.
Lead Product(s): Enavogliflozin
Therapeutic Area: Ophthalmology Product Name: DWRX2008
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
Daewoong Pharmaceutical has added benign masseteric hypertrophy (BMH), commonly known as the square jaw, to the indications for its botulinum toxin (BTX) product, Nabota.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Rare Diseases and Disorders Product Name: Nabota
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Under the agreement, Daewoong Pharmaceutical plans to expand its presence of a potassium-competitive acid blocker (P-CAB) drug Fexuclue (fexuprazan) in the African pharmaceutical market for gastroesophageal reflux disease (GERD).
Lead Product(s): Fexuprazan
Therapeutic Area: Gastroenterology Product Name: Fexuclue
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: COOPER PHARMA
Deal Size: $20.3 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2023
Details:
Under the terms of the termination agreement, Daewoong regains all rights to the commercialization and clinical development of Fexuclue (fexuprazan), a novel potassium-competitive acid blocker for the treatment of erosive esophagitis, in the U.S. and Canada.
Lead Product(s): Fexuprazan
Therapeutic Area: Gastroenterology Product Name: Fexuclue
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurogastrx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination June 05, 2023
Details:
HL036 (tanfanercept) is a novel, potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor alpha for the treatment of dry eye disease, co-developed with Daewoong Pharmaceutical.
Lead Product(s): Tanfanercept
Therapeutic Area: Ophthalmology Product Name: HL036
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Hanall Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
